Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast |  Colon |  Leukemia |  Lung |  Lymphoma |  Myelomas |  Pancreatic |  Prostate |  Solid Tumors |


  • Ruxolitinib/placeb+Cape met HEr2- Breast
    A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer (INCB 18424-268)

  • Ph1b/2 MLN0128 for ER+/HER2- bC
    A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination with Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment with Everolimus in Combination with Exemestane or Fulvestrant (C31001)
  • Trastuzumab versus Trastuzumab Emtansine (Kadcyla) in Her2+ Adjuvant Breast Cancer
    A Randomized, Multicenter, Open-label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in patients with Operable Her2-Positive Primary Breast Cancer
  • Fulvestrant +/- BKM120 in patients with metastatic Breast Cancer
    A Phase III randomized, double blind placebo controlled study of BKM120 with Fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment


  • Ruxolitinib or Place+Regoraf Ref CRC
    INCB 18424-267 A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

  • Imprime PGG® + Cetuximab in KRAS wildtype mCRC
    A Phase III Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer






  • INCB 18424-362
    A randomized, double-blind, phase 3 study of the JAK1/2 inhibitor, Ruxolitinib or Placebo in combination with Capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy


Solid Tumors